Table 3.

Comorbidities associated with bleeding in individuals with and without HHT

VariableHHT with bleedingNo HHT with bleedingP value
Percent or mean (standard error)
n (%) 648 (0.06%) 1 005 594 (99.94%)  
Congestive heart failure 26.7 18.3 < .001 
GERD 25.9 20.0 .001 
Hyperlipidemia 21.9 30.0 < .001 
Renal disease 17.6 20.9 .048 
Iron deficiency anemia 15.7 7.5 < .001 
Obesity 10.0 15.5 < .001 
Liver disease    
Cirrhosis 10.0 3.6 < .001 
Portal HTN 7.3 3.9 < .001 
HCV 3.4 1.3 < .001 
Postnecrotic cirrhosis 2.3 0.7 < .001 
Diabetes with complications 8.8 11.7 .023 
Anticoagulation 5.2 10.7 < .001 
Aspirin use 4.6 13.5 < .001 
Malignancy 4.0 10.1 < .001 
Inpatient mortality 1.9 3.6 .017 
Platelet transfusion 1.2 1.4 .653 
Blood or blood product transfusion 0.0 0.0 NA 
Length of stay (d) 5.5 (0.2) 6.0 (0.0) .043 
Charlson comorbidity score 2.3 (0.1) 2.6 (0.0) .005 
VariableHHT with bleedingNo HHT with bleedingP value
Percent or mean (standard error)
n (%) 648 (0.06%) 1 005 594 (99.94%)  
Congestive heart failure 26.7 18.3 < .001 
GERD 25.9 20.0 .001 
Hyperlipidemia 21.9 30.0 < .001 
Renal disease 17.6 20.9 .048 
Iron deficiency anemia 15.7 7.5 < .001 
Obesity 10.0 15.5 < .001 
Liver disease    
Cirrhosis 10.0 3.6 < .001 
Portal HTN 7.3 3.9 < .001 
HCV 3.4 1.3 < .001 
Postnecrotic cirrhosis 2.3 0.7 < .001 
Diabetes with complications 8.8 11.7 .023 
Anticoagulation 5.2 10.7 < .001 
Aspirin use 4.6 13.5 < .001 
Malignancy 4.0 10.1 < .001 
Inpatient mortality 1.9 3.6 .017 
Platelet transfusion 1.2 1.4 .653 
Blood or blood product transfusion 0.0 0.0 NA 
Length of stay (d) 5.5 (0.2) 6.0 (0.0) .043 
Charlson comorbidity score 2.3 (0.1) 2.6 (0.0) .005 

GERD, gastroesophageal reflux; NA, not available.

Close Modal

or Create an Account

Close Modal
Close Modal